Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02922907 · ClinicalTrials.gov registry record · NA
Rice Bran Supplementation in Treated HIV Infection
A NA study, sponsored by University of Southern California.
- Completed
- Registry status
- NA
- Development phase
- 24
- Enrollment target
NCT02922907 is a NA study that has completed, run by University of Southern California. The registered enrollment target is 24 participants.
The verdict
NCT02922907, a NA study, has completed, sponsored by University of Southern California.
- COMPLETED
- Registry status
- NA
- Development phase
- 24 participants
- Enrollment target
Study Summary
Double-blind placebo-controlled randomized trial of Arabinoxylan Rice Bran Supplementation for 12 weeks with BRM4 in HIV-infected participants with inadequate immune reconstitution.
Interventions
- DIETARY_SUPPLEMENT arabinoxylan rice bran
- DIETARY_SUPPLEMENT Placebo for arabinoxylan rice bran
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2017-03-24 |
| Est. Completion | 2019-12-03 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02922907
The ClinicalTrials.gov registry entry for NCT02922907 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Southern California, which has 617 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which arabinoxylan rice bran is the first listed.
NCT02922907 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02922907 about?
NCT02922907 is a clinical study titled "Rice Bran Supplementation in Treated HIV Infection". Double-blind placebo-controlled randomized trial of Arabinoxylan Rice Bran Supplementation for 12 weeks with BRM4 in HIV-infected participants with inadequate immune reconstitution.
What is the current status of trial NCT02922907?
This trial is currently completed. It is a NA study. The enrollment target is 24 participants. The study started on 2017-03-24. Estimated completion is 2019-12-03.
What interventions are being tested in trial NCT02922907?
The interventions under investigation include: arabinoxylan rice bran (DIETARY_SUPPLEMENT), Placebo for arabinoxylan rice bran (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT02922907?
This trial is sponsored by University of Southern California, which has 617 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.